Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of “Moderate Buy” by Analysts

Roivant Sciences Ltd. (NASDAQ:ROIVGet Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $16.50.

ROIV has been the subject of a number of recent analyst reports. HC Wainwright dropped their price objective on Roivant Sciences from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 14th. Deutsche Bank Aktiengesellschaft initiated coverage on Roivant Sciences in a report on Tuesday, December 12th. They issued a “buy” rating and a $14.00 price target for the company. Truist Financial reaffirmed a “buy” rating and set a $23.00 price objective on shares of Roivant Sciences in a research report on Monday, March 25th. Wolfe Research initiated coverage on Roivant Sciences in a research report on Thursday, February 15th. They set an “outperform” rating and a $17.00 price objective for the company. Finally, Bank of America upped their price objective on Roivant Sciences from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 2nd.

Read Our Latest Report on Roivant Sciences

Insider Buying and Selling at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the transaction, the chief operating officer now owns 532,207 shares in the company, valued at $5,811,700.44. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Roivant Sciences by 26.3% during the fourth quarter. Vanguard Group Inc. now owns 7,075,651 shares of the company’s stock worth $79,460,000 after purchasing an additional 1,473,085 shares during the period. Virtu Financial LLC bought a new position in shares of Roivant Sciences during the fourth quarter worth approximately $136,000. Price T Rowe Associates Inc. MD increased its stake in Roivant Sciences by 2.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,786,613 shares of the company’s stock worth $42,524,000 after acquiring an additional 74,131 shares during the period. Public Employees Retirement System of Ohio increased its stake in Roivant Sciences by 5.3% during the 4th quarter. Public Employees Retirement System of Ohio now owns 149,031 shares of the company’s stock worth $1,674,000 after acquiring an additional 7,459 shares during the period. Finally, Dagco Inc. bought a new position in Roivant Sciences during the 4th quarter worth $27,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 4.7 %

ROIV stock opened at $10.92 on Wednesday. The company has a market cap of $8.80 billion, a P/E ratio of 2.10 and a beta of 1.34. Roivant Sciences has a twelve month low of $6.97 and a twelve month high of $13.24. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $10.75 and a 200-day moving average of $10.35.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. As a group, equities research analysts expect that Roivant Sciences will post -1.36 EPS for the current year.

Roivant Sciences Company Profile

(Get Free Report

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.